2-ARA-LysoPtdEtn

ICR mice (4-6 weeks of age, 29-30 g body weight, intraperitoneal injected 1 mg Zymosan A to establish a eritonitis model)^[1]

15 µg/kg; 50 µg/kg; 150 µg/kg

p.o.; single dose

Suppressed Zymosan A-induced plasma leakage by 17% at 50 µg/kg and by 36% at 150 µg/kg; ED₅₀ for plasma leakage inhibition was 221 µg/kg.
Decreased total leukocyte infiltration by 56% at 150 µg/kg; ED₅₀ for leukocyte infiltration inhibition was 123 µg/kg.
Dose-dependently reduced Zymosan A-induced formation of LTC₄ (ED₅₀ = 132 µg/kg), LTB₄ (ED₅₀ = 139 µg/kg), and 12-HETE.
Dose-dependently reduced Zymosan A-induced levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6; increased anti-inflammatory cytokine IL-10 levels by approximately five-fold at 150 µg/kg compared to the Zymosan A-challenged group.
Diminished Zymosan A-induced nitric oxide production by 60% at 50 µg/kg and by 70% at 150 µg/kg.
Dose-dependently increased peritoneal levels of 15-HETE (3.5-fold at 15 µg/kg, 5-fold at 50 µg/kg, 9-fold at 150 µg/kg) and LXA₄ (2-fold at 15 µg/kg, 4-fold at 50 µg/kg, 5.5-fold at 150 µg/kg) compared to the Zymosan A-challenged group.
Reduced total leukocyte infiltration by ~23% at 15 hours, ~21% at 20 hours, and ~33% at 24 hours when administered 12 hours after Zymosan A treatment compared to the Zymosan A-alone group.